ZHENG Aiqing, MU Haiyu, LI Jing, QU Yajing, LIANG Keming. Department of Oncology, Affiliated Hostipal of Logistics University of CAPF, Tianjin 300162, China
Abstract：Objective To retrospectively analyze the efficacy and toxicity of unresectable hilar cholangiocarcinoma treated with concurrent capecitabine and radiation therapy. Methods Nineteen patients with unresectable hilar cholangiocarcinoma underwent concurrent chemo-radiotherapy protocol from May 2005 through March 2012. All patients received three-dimensional conformal radiotherapy (3D-CRT), 5 times a week at 2 Gy per fraction per day to a total dose of 50 Gy. Concurrent chronomodulated capecitabine was administered on days of irradiation in a dosage of 1 g in the morning and 2 g in the evening. Results All patients completed the treatment course. Twelve patients(63.2%)achieved a PR, and seven (36.8%) achieved a SD at the first follow-up examination. The median survival time was 12.7 months (range 4.3 to 20.8 months) and the median disease-free survival time was 9.3 months (range 3.6 to 18.6 months). A cumulative grade 3 toxicity was observed in 3 out of the 19 patients (15.8%). No patient had any grade 4 toxicity. Conclusions Concurrent capecitabine and radiation therapy is effective and tolerable in patients with unresectable hilar cholangiocarcinoma.
2014, Vol. 25 
